Protalix BioTherapeutics Reveals PRX-115 Data at ACR Convergence
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a pioneering biopharmaceutical firm, is poised to present pivotal findings on their phase I clinical trial for PRX-115. This recombinant PEGylated uricase product candidate is specifically designed to address uncontrolled gout, a condition affecting many individuals. The unveiling of this data will take place during a late-breaking poster session at the renowned American College of Rheumatology (ACR) Convergence 2024.
Details of the Presentation
The presentation titled "Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels" will be shared during the late-breaking posters session. This session is scheduled for November 18, 2024, from 10:30 AM to 12:30 PM Eastern Standard Time.
Presenting Author
The audience can look forward to insights from Dr. Orit Cohen Barak from Protalix Ltd. This session promises to shed light on the potential impacts of PRX-115, emphasizing its effectiveness in managing high urate levels.
Abstract Accessibility
The abstract detailing this innovative study can be viewed on the ACR Convergence 2024 website, ensuring that interested professionals can easily access this critical information. Furthermore, a copy of the poster will be available on the Protalix website, allowing broader access to their findings.
About Protalix BioTherapeutics
Protalix is distinguished in the biopharmaceutical landscape for its specialization in developing and commercializing recombinant therapeutic proteins via ProCellEx, their proprietary plant cell-based expression system. This pioneering company holds the unique achievement of acquiring U.S. FDA approval for a protein generated through a plant cell-based system. This innovative approach not only transforms the production of recombinant proteins but also positions Protalix at the forefront of biopharmaceutical advancements.
Among its notable endeavors, Protalix licensed worldwide rights to taliglucerase alfa from Pfizer Inc. for Gaucher disease treatment, maintaining full rights in Brazil. Their second product, Elfabrio, achieved significant recognition with FDA and European Medicines Agency approval, accentuating the company's commitment to medical innovation.
The Development Pipeline
Protalix’s robust development pipeline showcases a range of recombinant therapeutic proteins targeting well-established pharmaceutical markets. Currently highlighted are the product candidates like PRX-115, which focuses on uncontrolled gout treatment, and PRX-119, aimed at treating NETs-related diseases. This diversity points to Protalix’s adaptability and forward-thinking strategies in addressing various medical needs.
Strategic Partnerships
In tightening its position in the industry, Protalix has formed crucial partnerships, including a collaboration with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Such alliances are vital for the continued growth and reach of their innovative treatments.
Frequently Asked Questions
What is PRX-115?
PRX-115 is a recombinant PEGylated uricase product candidate developed by Protalix BioTherapeutics, aimed at treating uncontrolled gout.
When will the data from the phase I trial be presented?
The data will be presented at the ACR Convergence 2024 on November 18, 2024, during the late-breaking poster session.
Who will present the findings on PRX-115?
Dr. Orit Cohen Barak from Protalix Ltd. is the presenting author for this crucial session.
How does Protalix BioTherapeutics stand out in the biopharmaceutical industry?
Protalix is unique for its plant cell-based expression system, ProCellEx, and for being the first to receive FDA approval for a protein produced via this innovative method.
What other products are in Protalix’s development pipeline?
Aside from PRX-115, Protalix is working on PRX-119 and several other recombinant therapeutic proteins targeting established pharmaceutical markets.
